Award type :
Product Development Award
Product Development Award
Product type :
Diagnostics
Diagnostics
Award year :
2021
2021
Project start date :
04 / 30 / 2021
04 / 30 / 2021
Project end date :
05 / 31 / 2024
05 / 31 / 2024
Project duration (months) :
25
25
Development stage :
Late Validation, Clinical Validation
Late Validation, Clinical Validation
Target disease :
Tuberculosis
Tuberculosis
Region served :
World
World
Recipient organization / Country of funding recipient organization :
SD Biosensor / Republic of Korea
SD Biosensor / Republic of Korea
Collaborator(s) / Country :
Foundation for Innovative New Diagnostics (FIND) / Switzerland
Foundation for Innovative New Diagnostics (FIND) / Switzerland
Funding amount(KRW) :
2,138,770,613
2,138,770,613
In response to the need for TB lipoarbinomannan (LAM) assay tests with higher sensitivity, SD Biosensor has collaborated with FIND to develop a TB LAM antigen-based test by incorporating 2nd generation monoclonal antibodies (mAbs). Through technology transfer of the 2nd generation mAbs from FIND, SD Biosensor aims to incorporate its existing Standard F platform, which is well suited for use in remote and low resource settings, along with scaling up and performance assessment. The development of such diagnostics for low resource settings can reduce the time to result and improve accuracy.